Following the announced share-swap merger between Easywell Biomedicals and Genovate Biotechnology, Awi Chairman Han-Fei Lin—a veteran of M&A from his tenure at MediaTek and Citigroup—expressed high confidence in the deal’s long-term value. Lin projects that Genovate Biotechnology’s revenue will double within five years, with profit growth outpacing revenue gains.

• "The Fleet Strategy": Lin emphasized that Taiwan’s pharmaceutical industry, which represents less than 1% of global GDP, must consolidate across platforms and regions to compete globally.
• Supply Chain Resilience: The merger allows Awi to leverage its US FDA-approved cGMP facility in New Jersey alongside Genovate Biotechnology’s production lines in Taiwan. Awi’s proprietary long-acting controlled-release technology, currently expanding from oral to injectable forms, can now be offshored to Genovate Biotechnology for production, providing a flexible "dual-base" manufacturing model.
• Pipeline Momentum: Awi currently has over five 505(b)(2) products in development, including treatments for epilepsy, ALS, and anti-emetic injectables. Additionally, Awi’s blockbuster angina medication in China has already established a robust local sales network, positioning 2026 to be the company's strongest year since the current management took over.

Resource: 易威、健亞整併 易威董座:健亞未來5年營收拚翻倍